The Advisory Committee on Immunization Practices, a group of experts that makes recommendations to the Centers for Disease Control for which vaccines children and adults should get, voted to recommend the spray over the shot late Wednesday. The panel said studies show children who had the spray are half as likely to get the flu as those who had the shot.
So far, there is only one nasal spray flu vaccine available — AstraZeneca's FluMist, which was approved in 2003 for people ages 2 to 49.
The spray differs from the needle-based vaccine in another important way — it's made from a live, weakened influenza virus, while the shot drums up an immune response using killed virus. Studies have shown the spray can lead to a stronger immune response in children who have not had the flu before, but the same may not hold true for adults.
Of course, it's important to note that the nasal spray version of the vaccine isn't recommended for all kids (or adults, for that matter), so ask your pediatrician which version of the vaccine is best for your child.